Inovio Pharmaceuticals (NASDAQ:INO) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Inovio Pharmaceuticals (NASDAQ:INO) from a hold rating to a sell rating in a report issued on Saturday morning.

Several other research analysts have also issued reports on INO. Weiss Ratings lowered shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.50.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ:INO opened at $1.30 on Friday. Inovio Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $2.98. The stock has a market cap of $106.95 million, a price-to-earnings ratio of -0.90 and a beta of 1.43. The stock’s 50 day moving average price is $1.38 and its 200 day moving average price is $1.71.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. On average, sell-side analysts expect that Inovio Pharmaceuticals will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the 1st quarter valued at $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $234,000. Jane Street Group LLC lifted its stake in shares of Inovio Pharmaceuticals by 221.2% in the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 27,329 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $27,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.